ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for discussion Cadastre-se para interagir em nossos fóruns de ativos e discutir com investidores ideias semelhantes.

REGN Regeneron Pharmaceuticals Inc

896,82
2,83 (0,32%)
19 Abr 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Regeneron Pharmaceuticals Inc REGN NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
2,83 0,32% 896,82 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
913,97 891,46 920,73 896,82 893,99
mais cotações »

Notícias Recentes

Data Hora Fonte Título
16/04/202408:18IHMARKETNEWSEricsson Soars with 66% Net Profit Growth; Live Nation Under..
11/04/202408:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
07/04/202417:00GLOBELinvoseltamab Pivotal Data Presented at AACR Reinforce High..
01/04/202417:05GLOBERegeneron to Report First Quarter 2024 Financial and..
25/03/202408:00GLOBERegeneron Provides Update on Biologics License Application..
13/03/202400:55PRNUSHigh School Seniors Win $1.8 Million at Regeneron Science..
12/03/202422:30GLOBEHigh School Seniors Win $1.8 Million at Regeneron Science..
11/03/202408:00GLOBEPraluent® (alirocumab) Injection Receives FDA Approval to..
08/03/202409:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet..
23/02/202403:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
21/02/202409:00GLOBELinvoseltamab BLA for Treatment of Relapsed/Refractory..
16/02/202402:59GLOBEJapan First in the World to Approve Dupixent® (dupilumab)..
06/02/202418:05GLOBERegeneron Announces Investor Conference Presentations
02/02/202408:30GLOBERegeneron Reports Fourth Quarter and Full Year 2023..
02/02/202408:00GLOBELinvoseltamab Receives EMA Filing Acceptance for Treatment..
30/01/202411:25APSBiotech Shares Soar Premarket On Sale Of R&D Assets
30/01/202409:00GLOBERegeneron Announces Formation of Regeneron Cell Medicines..
25/01/202416:29GLOBEDupixent® (dupilumab) FDA Approved as First and Only..
24/01/202414:05PRNUSTop 40 High School Scientists in Prestigious Regeneron..
24/01/202414:00GLOBETop 40 High School Scientists in Prestigious Regeneron..
16/01/202409:00GLOBEDupixent® (dupilumab) U.S. Label Updated with Data Further..
08/01/202409:30PRNUSMedison Pharma Announces Agreement with Regeneron..
05/01/202418:05GLOBERegeneron to Report Fourth Quarter and Full Year 2023..
18/12/202318:05GLOBERegeneron Announces Presentation at the 42nd Annual J.P...
11/12/202309:30GLOBERegeneron Named on Dow Jones Sustainability World Index for..
10/12/202321:30GLOBELatest Odronextamab Data in Relapsed/Refractory Follicular..
10/12/202314:30GLOBEUpdated Odronextamab Data from Relapsed/Refractory Diffuse..
07/12/202309:00GLOBEUpdated Linvoseltamab Pivotal Data Demonstrated Strong Rates..
07/12/202304:30GLOBERegeneron to Share Progress of Novel Combination Therapies..
30/11/202318:05GLOBERegeneron to Host Investor Call and Webcast on December 14,..
27/11/202303:30GLOBEDupixent® (dupilumab) Significantly Reduced COPD..
16/11/202313:39DJNRegeneron Currently Down Eight Consecutive Days, On Track..
15/11/202318:05GLOBERegeneron Announces Investor Conference Presentation
15/11/202313:29DJNRegeneron Pharmaceuticals Currently Down Seven Consecutive..
13/11/202311:00GLOBERegeneron Commits $34 Million Over Five Years to Continue to..
10/11/202312:00DJNBayer Gets CHMP Backing for Higher-Dose Eylea in Two Major..
03/11/202308:32IHMARKETNEWSFriday’s Wall Street Highlights: Apple, Bill Holdings,..
03/11/202308:00GLOBERegeneron to Highlight Scientific Advancements Across..
02/11/202307:30GLOBERegeneron Reports Third Quarter 2023 Financial and Operating..
01/11/202317:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Data Presentations at..
26/10/202317:00GLOBERegeneron Shares Preliminary Results Showing Gene Therapy..
25/10/202317:05GLOBERegeneron Announces Investor Conference Presentations
22/10/202315:59GLOBEDupixent® (dupilumab) Phase 3 Results Show Sustained..
21/10/202309:48GLOBELibtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates..
20/10/202318:00GLOBERegeneron and Sanofi Provide Update on Dupixent® (dupilumab)..
18/10/202310:30GLOBERegeneron builds on Together for CHANGE™ initiative with..
18/10/202310:00GLOBETogether for CHANGE Genomics and Equity Initiative Launched..
15/10/202319:05GLOBERegeneron to Showcase Progress from Innovative Oncology..
13/10/202312:57DJNRegeneron Pharmaceuticals on Pace for Record High Close --..
05/10/202310:43GLOBEEYLEA® HD (aflibercept) Injection 8 mg Two-year Results from..

Seu Histórico Recente

Delayed Upgrade Clock